[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Shariati et al., 2013 - Google Patents

Journal of Biology and Today's World

Shariati et al., 2013

View PDF
Document ID
8421820928224806358
Author
Shariati F
Abbasi S
Publication year

External Links

Snippet

Breast cancer is one of the most common cancers among women in the United States. It is estimated that approximately 1 in 8 women will suffer from the disease at some point in their lifetime. In the recent years, knowledge about cancer biomarker has increased. Biomarkres …
Continue reading at citeseerx.ist.psu.edu (PDF) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/574—Immunoassay; Biospecific binding assay for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Similar Documents

Publication Publication Date Title
Nahta et al. Herceptin: mechanisms of action and resistance
Yarden Biology of HER2 and its importance in breast cancer
Browne et al. HER-2 signaling and inhibition in breast cancer
Albanell et al. Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4
Eiermann et al. Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: pivotal trial data
Canonici et al. Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer
Barros et al. Understanding the HER family in breast cancer: interaction with ligands, dimerization and treatments
US9783456B1 (en) Method for inhibiting cell growth using anti-ErbB-3 and anti-ErbB-2 antibodies
Valabrega et al. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer
Nunes et al. The HER2 extracellular domain as a prognostic and predictive factor in breast cancer
Fiszman et al. Molecular mechanisms of trastuzumab resistance in HER2 overexpressing breast cancer
Park et al. Unraveling the biologic and clinical complexities of HER2
KR20190140945A (en) ErbB-2 and ErbB-3 binding bispecific antibodies for treating cells with NRG1 fusion genes
Arteaga Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer
KR20160092992A (en) Cancer biomarkers and uses thereof
Zahnow ErbB receptors and their ligands in the breast
Kim et al. Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells
EP3030268B1 (en) Combination of ifn-gamma with anti-erbb antibody for the treatment of cancers
TW201642897A (en) HER2 binding agent therapies
Ghedini et al. Shed HER2 extracellular domain in HER2‐mediated tumor growth and in trastuzumab susceptibility
JP2024071393A (en) Means and methods for treating subjects with her2 and her3 positive cancer
Zhuang et al. Efficacy and immune mechanisms of cetuximab for the treatment of metastatic colorectal cancer
Shariati et al. Journal of Biology and Today's World
Porzia et al. Attenuation of PI3K/Akt-mediated tumorigenic signals through PTEN activation by DNA vaccine-induced anti-ErbB2 antibodies
Stanek et al. HER-3 molecular classification, expression of PD-L1 and clinical importance in breast cancer.